1. Scrip
  2. >>Therapy Areas

Strike two for Lpath, employees out

 
• By Lisa LaMotta

Lpath hit another round of bad luck when its lipid-targeted eye drug failed to show a statistically significant benefit in a Phase II study of patients with wet age-related macular degeneration, forcing the company to cut costs and employees.

The San Diego biotech announced 20 May that iSONEP failed to improve visual clarity for the 158 wet AMD patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.